Adoption of our core behaviours: curiosity, adaptability and accountability across the organisation are crucial to our Focused Innovator strategy, which is committed to advancing brain health and transforming the lives of the patients we serve.

We are guided by the principles of our Code of Conduct whilst upholding adherence to applicable laws, codes and regulatory requirements. In addition, our commitment in striving to achieve the goals outlined in our Sustainability Strategy continues to be a key component of how we conduct our business ethically.

Lundbeck’s Code of Conduct is central to our ethics and compliance culture. It conveys our commitments and expectations to all employees and third parties working on Lundbeck’s behalf. For this reason, it is essential that everyone observes the Code of Conduct and, in addition, adheres to any laws, codes and regulations that may impose stricter standards.

Our Code of Conduct reflects both internal and external requirements and adheres, among others, to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Code of Practice. The IFPMA, of which Lundbeck is a member, is a global industry standard on how pharmaceutical companies are expected to interact with its stakeholders. 

It is Lundbeck’s Executive Management that defines and sets the tone for our Code of Conduct by means of a Compliance Committee represented by key business functions. The Chief Ethics & Compliance Officer is responsible for updating the Compliance Committee and the Board of Directors’ Audit Committee on all ethics and compliance matters. In turn, the Compliance Committee endorses those proposals to the Code of Conduct that will ensure ethical and compliance standards are maintained.

Lundbeck’s Compliance Programme encompasses key elements that are essential in ensuring a successful governance structure across its organisation with the purpose of protecting its business.

It is a framework designed to ensure governance is in place and aligns with applicable regulations to mitigate potential business and behavioural risks. Lundbeck’s Compliance Committee, together with internal audits, plays a pivotal role in continuously monitoring and safeguarding our business activities.

At Lundbeck, we encourage ongoing dialogue on ethics and compliance among colleagues and managers. Our Senior Management is committed to supporting employees in making ethical decisions. Our global network of Regional Compliance Officers, led by Lundbeck’s Chief Ethics & Compliance Officer, provides guidance and advice to the business.

Additionally, we invest in annual training and awareness activities that translate the principles of our Code of Conduct into ethical actions. Advice and guidance on ethical and compliance matters is always on-hand. For serious compliance concerns, these can be reported confidentially, and without fear of retribution, to Lundbeck’s Compliance Hotline.

Promotion of medicinal products is strictly regulated and monitored by local authorities. We are committed to complying with applicable regulations. This means maintaining processes and providing extensive training to ensure that promotional activities are appropriately evaluated and approved.

Lundbeck’s promotional and advertising review committee assesses and approves promotional communication materials produced at our headquarters. Our affiliates are responsible for ensuring that promotional materials are reviewed and approved in accordance with local laws, regulations and industry codes, before the materials are used within the specific local market.

In the UK all materials are reviewed and approved locally in accordance with The Association of the British Pharmaceutical Industry (ABPI) Code of Practice, which is administered and regulated by the Prescription Medicines Code of Practice Authority (PMCPA).